Source - RNS
RNS Number : 6199J
Abzena PLC
13 September 2016


Hardman Research: Servicing the royalty stream

Servicing the royalty stream: Abzena is an integrated group offering a broad range of services and technologies to improve the chances of discovering and developing effective biopharmaceutical drugs. With strong footprints in both the US and UK, the company provides a fee-for-service offering with the aim of embedding its technology - 'Abzena Inside' - into commercial products on which it will derive a long-term royalty stream. To date, from 40 technology agreements, partners have initiated clinical development with 12 'Abzena Inside' products. The service business easily covers the current valuation suggesting that the significant royalty stream is in the price for nothing. 


Please click here for the full report:



To contact us:   

Hardman & Co

11/12 Tokenhouse Yard 



Contact: Dr Martin Hall [email protected] 

Dr Dorothea Hill

[email protected]

Dr Gregoire Pave

[email protected]

Telephone: +44 20 7929 3399

Follow us on Twitter @HardmanandCo


About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge.  Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.


Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.


Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies.  It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.



This information is provided by RNS
The company news service from the London Stock Exchange